Kolkhir, Pavel http://orcid.org/0000-0001-5380-8132
Akdis, Cezmi A.
Akdis, Mübeccel
Bachert, Claus
Bieber, Thomas http://orcid.org/0000-0002-8800-3817
Canonica, Giorgio Walter
Guttman-Yassky, Emma http://orcid.org/0000-0002-9363-324X
Metz, Martin http://orcid.org/0000-0002-4070-9976
Mullol, Joaquim
Palomares, Oscar
Renz, Harald http://orcid.org/0000-0003-0602-7215
Ständer, Sonja
Zuberbier, Torsten
Maurer, Marcus http://orcid.org/0000-0002-4121-481X
Article History
Accepted: 16 June 2023
First Online: 1 August 2023
Competing interests
: P.K. received speaker’s fees, honoraria or travel support from Novartis, ValenzaBio, Roche and Takeda. C.A.A. has received research grants from the Swiss National Science Foundation, European Union (EU CURE, EU SynAir-G), Novartis Research Institutes (Basel, Switzerland), Stanford University (Redwood City, CA, USA), Seed Health (Boston, MA, USA) and SciBase (Stockholm, Sweden); is the Co-Chair for European Academy of Allergy and Clinical Immunology (EAACI) Guidelines on Environmental Science in Allergic diseases and Asthma; is Chair of the EAACI Epithelial Cell Biology Working Group; is on the Advisory Boards of Sanofi/Regeneron (Bern, Switzerland, New York, USA), Stanford University Sean Parker Asthma Allergy Center (CA, USA), Novartis (Basel, Switzerland), Glaxo Smith Kline (Zurich, Switzerland), Bristol-Myers Squibb (New York, USA), Seed Health (Boston, MA, USA) and SciBase (Stockholm, Sweden); and is Editor-in-Chief of <i>Allergy</i>. M.A. received research grants from Swiss National Foundation Sean Parker allergy centre Seed grant, Leading House Swiss-Columbia research grant, Horizon 2020 and EU Grant SynAir-G; and is on the advisory board for LEO foundation, SIC Copenhagen, Denmark and Sean Parker Allergy Center (Stanford, CA, USA). C.B. is an Advisory Board member and speaker for Novartis, GSK, AstraZeneca, Sanofi, ALK, Bionorica and Mylan. T.B. was speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN Pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, MSD, Medac, Novartis, Numab, OM Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB and Union Therapeutics; and is founder and chairman of the board of the non-profit biotech ‘Davos Biosciences’ within the international Kühne-Foundation. G.W.C. received research grants from as well as being a lecturer for or having received advisory board fees from A. Menarini, Anallergo, Allergy Therapeutics, AstraZeneca, Chiesi Farmaceutici, Faes, Firma, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Innovacaremd, Novartis, Om Pharma, RedMaple, Sanofi-Aventis, Sanofi-Genzyme, Stallergenes-Greer, Uriach Pharma, ThermoFisher and Valeas. E.G.-Y. received research grants (paid to the institution) from Boerhinger-Ingelhiem, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Aslan, Regeneron, Anaptysbio, Concert and Janssen. M. Metz has honoraria as a speaker and/or consultant for AbbVie, Amgen, ArgenX, AstraZeneca, Bayer, Celldex, Celgene, Escient, Galderma, Grünenthal, GSK, Menlo, Novartis, Pfizer, Pharvaris, Regeneron, Roche, Sanofi-Aventis, Teva, Third Harmonic Bio and Viforpharma. J.M. is or has been a member of national and international scientific advisory boards, consulted and received fees for lectures and grants for research projects or clinical trials from AstraZeneca, Genentech-Roche, GSK, LETI, Menarini, MSD, Mitsubishi-Tanabe, Viatris/MEDA Pharma, Novartis, OPTINOSE, Proctor & Gamble, Sanofi-Genzyme & Regeneron, UCB Pharma and NOUCOR/Uriach Group; received financial support from AGAUR and ISCiii; and is Editor-in-Chief of <i>Current Treatment Options in Allergy</i>. O.P. has received fees for lectures or participation in Advisory Boards from AstraZeneca, GSK, Inmunotek SL, Novartis, Pfizer, Sanofi-Genzyme and Regeneron; and has received research grants from MINECO, MICINNIN and CAM and research unrestricted grants from Inmunotek SL, Novartis SL and AstraZeneca. H.R. is supported by the German Lung Center (DZL) and the Universities Giessen and Marburg Lung Center (UGLMC), the MIRACUM Consortium of the Medical Informatics Initiative, the Stiftung Pathobiochemistry and DAAD and GIZ Hospital Partnership Programme, the DFG, BMBF, EU and Land Hessen; has received speakers’ honorarium from Allergopharma, Novartis, ThermoFisher, Danone, Bencard and Stallergenes; has consulted for Sterna-biologicals (co-founder); and is Associate Editor of <i>Journal of Allergy and Clinical Immunology</i> (JACI). S.S. was speaker and/or consultant and/or investigator for and/or has received research funding from Abbvie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, German Research Foundation (DFG), Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor and WebMD. T.Z. has received industry consulting, research grants and/or honoraria from Abivax, Allakos, AImmune, Ajanta Pharma, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, BioCryst, Celldex, FAES, HAL, Henkel, Kryolan, Leti, Lofarma, L’Oreal, Meda, Medi Wound, Menarini, Merck, MibeTec, MMV Medicines for Malaria Venture, MSD, Novartis, PCM Scientific, Pfizer, Sanofi, Sanoflore, Stallergenes, Takeda, Teva and UCB. M. Maurer is or recently was a speaker and/or adviser for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB and Uriach.